8-K: Avidity Biosciences Announces Positive Initial Data from FSHD Trial, Expands Share Plan

Avidity Biosciences reported significant reductions in DUX4 regulated genes and positive trends in functional improvements in its Phase 1/2 trial for FSHD, while also increasing the number of shares available under its incentive plan.

Summary

• Avidity Biosciences announced positive initial results from its Phase 1/2 FORTITUDE trial of delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD).
• The trial demonstrated greater than 50% mean reductions in DUX4 regulated genes in muscle tissue across multiple panels.
• All participants treated with del-brax showed reductions greater than 20% in DUX4 regulated genes.
• The study also showed mean reductions of 25% or greater in a novel circulating biomarker and creatine kinase.
• There were trends of functional improvements, including increased strength in upper and lower limb muscles, and improved muscle function as measured by reachable workspace compared to placebo and a natural history study.
• The safety and tolerability of del-brax were favorable, with all adverse events being mild or moderate, and no serious adverse events or discontinuations.
• The company plans to initiate a biomarker cohort in the second half of 2024 and a functional cohort in the first half of 2025 for the Phase 3 portion of the FORTITUDE trial.
• Avidity also increased the authorized number of shares under its 2022 Employment Inducement Incentive Award Plan from 1,500,000 to 4,500,000 shares.
• The company also announced the initiation of the global Phase 3 HARBOR trial of del-desiran for myotonic dystrophy type 1 and expects to announce data from the 5 mg/kg cohort in its Phase 1/2 EXPLORE44 trial for Duchenne muscular dystrophy in the third quarter of 2024.
• A rare precision cardiology program is anticipated to be announced in the second half of 2024.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results, a clear path forward with Phase 3 plans, and a strong pipeline. The increase in the share plan is also a positive sign for future growth. The sentiment is very optimistic.

Positives

• The trial results showed a significant reduction in DUX4 regulated genes, which is a key factor in FSHD.
• The functional improvements observed, such as increased muscle strength and reachable workspace, are promising for patients.
• The safety and tolerability profile of del-brax was favorable, with no serious adverse events or discontinuations.
• The company is moving forward with plans to initiate Phase 3 cohorts, indicating confidence in the drug's potential.
• The increase in the share plan suggests the company is preparing for future growth and employee incentives.
• The initiation of the Phase 3 HARBOR trial and upcoming data readouts for other programs demonstrate a strong pipeline.

Negatives

• The data presented is from an initial assessment and may not be indicative of final results.
• The most common treatment emergent adverse events were fatigue and rash, each occurring in 25% of participants.
• The company is still early in its development efforts, and the approach to drug development is unproven.
• There are risks associated with clinical trials, including potential delays and unexpected adverse side effects.

Risks

• Preliminary results of the clinical trial may not be indicative of final results, and further analysis may lead to different conclusions.
• Unexpected adverse side effects or inadequate efficacy of the product candidates may delay or limit their development, regulatory approval, or commercialization.
• The planned additional cohorts in the FORTITUDE trial may not support the registration of del-brax.
• The company's approach to drug discovery and development is unproven, and there is no guarantee of commercial success.
• There are potential delays in the commencement, enrollment, data readouts, and completion of preclinical studies or clinical trials.
• The company is dependent on third parties for preclinical and clinical testing and product manufacturing.
• Regulatory developments in the United States and foreign countries could impact the company's plans.

Future Outlook

Avidity anticipates initiating potential Phase 3 cohorts in the FORTITUDE trial, including a biomarker cohort in the second half of 2024 and a functional cohort in the first half of 2025. The company also expects to announce data from the 5 mg/kg cohort in its Phase 1/2 EXPLORE44 trial in the third quarter of 2024 and a rare precision cardiology program in the second half of 2024.

Management Comments

• Avidity is accelerating del-brax toward approval due to positive data.
• The company believes del-brax has the potential to be a first-in-class and best-in-class treatment for FSHD.
• Avidity is focused on delivering for people living with FSHD.
• The company is leading the field in directly targeting DUX4.

Industry Context

This announcement is significant in the context of rare disease drug development, particularly for FSHD, where there are limited treatment options. The positive data from the FORTITUDE trial positions Avidity as a potential leader in this space, and the company's focus on RNA therapeutics aligns with broader industry trends in precision medicine.

Comparison to Industry Standards

• The reported greater than 50% reduction in DUX4 regulated genes is a significant result compared to other experimental therapies for FSHD, which often show less dramatic effects on the underlying disease mechanism.
• The trends of functional improvement, including increased muscle strength and reachable workspace, are also notable, as many therapies struggle to demonstrate clear functional benefits in FSHD patients.
• The favorable safety and tolerability profile is also important, as many experimental therapies have significant side effects that limit their use.
• The use of a novel circulating biomarker for monitoring treatment response is an innovative approach that could accelerate drug development and improve patient outcomes.
• The company's approach of using RNA therapeutics to target the root cause of the disease is consistent with the latest trends in drug development for genetic disorders.
• The initiation of a Phase 3 trial for del-desiran in myotonic dystrophy type 1 is also a positive sign, as it demonstrates the company's commitment to developing therapies for multiple rare diseases.

Corporate Governance

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the company's progress in developing treatments for rare diseases.
• Employees may benefit from the increased share plan, which could provide additional incentives and rewards.
• Patients with FSHD and their families may have increased hope for a potential treatment option.
• The company's progress could also have a positive impact on the broader scientific community and the development of RNA therapeutics.

Next Steps

• Initiate a biomarker cohort in the second half of 2024 for the Phase 3 portion of the FORTITUDE trial.
• Initiate a functional cohort in the first half of 2025 for the Phase 3 portion of the FORTITUDE trial.
• Announce data from the 5 mg/kg cohort in the Phase 1/2 EXPLORE44 trial for Duchenne muscular dystrophy in the third quarter of 2024.
• Announce a rare precision cardiology program in the second half of 2024.

Key Dates

Keywords

FSHD, delpacibart braxlosiran, del-brax, DUX4, muscular dystrophy, RNA therapeutics, clinical trial, FORTITUDE trial, biomarker, muscle strength, reachable workspace, gene expression, AOC platform, myotonic dystrophy, Duchenne muscular dystrophy